Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Exploring deubiquitinase MYSM1 as a novel drag-target for B cell lymphoma
FY 2023-24
Summary
Non-Hodgkin lymphoma is the 6th most common type of cancer and affects the cells of the blood and immune system. The 5-year survival of the patients remains at only 68%, and the subgroup of patients carrying genetic changes that result in a hyperactivation of protein MYC are particularly difficult to treat. Therefore, new therapies for non-Hodgkin lymphoma are urgently needed. Our research team demonstrated that the protein MYSM1 cooperates with MYC to regulate gene expression in the cancer cells. Using mouse models of non-Hodgkin lymphoma, we established that the loss of MYSM1 protein expression or of its catalytic activity in the cancer cells strongly protected against the lymphoma disease progression. These studies suggest MYSM1 as a promising novel drug-target for non-Hodgkin lymphoma, however, to date all the data on MYSM1 in cancer cells comes from mouse models. My research project will for the first time advance the studies of MYSM1 in lymphoma from mouse to human and encompasses the following studies. (1) In ongoing work, I am targeting the MYSM1 gene in a panel of human lymphoma cell lines with CRISPR-Cas9. As the project develops, I will analyze: (2) the effects of MYSM1-loss on the physiology of the human lymphoma cells, and (3) the mechanisms that MYSM1 uses to regulate MYC protein functions in the cancer cells. Overall, my work will advance the development of MYSM1 as a drug-target for B cell lymphoma.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506387
Name
Najm Nay
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring deubiquitinase MYSM1 as a novel drag-target for B cell lymphoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
B-Cell Lymphoma; Cancer Cell Physiology; Cancer Therapies; Cloning; Crispr-Targeting; Guided Rna; Human B-Cell Lymphoma Lines; Lymphoma; Myc Oncogenic Function; Mysm1 Knockout
Abstract
Non-Hodgkin lymphoma is the 6th most common type of cancer and affects the cells of the blood and immune system. The 5-year survival of the patients remains at only 68%, and the subgroup of patients carrying genetic changes that result in a hyperactivation of protein MYC are particularly difficult to treat. Therefore, new therapies for non-Hodgkin lymphoma are urgently needed. Our research team demonstrated that the protein MYSM1 cooperates with MYC to regulate gene expression in the cancer cells. Using mouse models of non-Hodgkin lymphoma, we established that the loss of MYSM1 protein expression or of its catalytic activity in the cancer cells strongly protected against the lymphoma disease progression. These studies suggest MYSM1 as a promising novel drug-target for non-Hodgkin lymphoma, however, to date all the data on MYSM1 in cancer cells comes from mouse models. My research project will for the first time advance the studies of MYSM1 in lymphoma from mouse to human and encompasses the following studies. (1) In ongoing work, I am targeting the MYSM1 gene in a panel of human lymphoma cell lines with CRISPR-Cas9. As the project develops, I will analyze: (2) the effects of MYSM1-loss on the physiology of the human lymphoma cells, and (3) the mechanisms that MYSM1 uses to regulate MYC protein functions in the cancer cells. Overall, my work will advance the development of MYSM1 as a drug-target for B cell lymphoma.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Najm, Nay
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~